NVCT
Price:
$10.81
Market Cap:
$201.64M
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.[Read more]
Industry
Biotechnology
IPO Date
2022-02-04
Stock Exchange
NASDAQ
Ticker
NVCT
According to Nuvectis Pharma, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -9.08. This represents a change of 40.90% compared to the average of -6.44 of the last 4 quarters.
The mean historical PE Ratio of Nuvectis Pharma, Inc. over the last ten years is -1036.84. The current -9.08 PE Ratio has changed -12.43% with respect to the historical average. Over the past ten years (40 quarters), NVCT's PE Ratio was at its highest in in the June 2021 quarter at -1.74. The PE Ratio was at its lowest in in the March 2021 quarter at -449.27.
Average
-1036.84
Median
-5.44
Minimum
-4133.28
Maximum
-3.21
Discovering the peaks and valleys of Nuvectis Pharma, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 57.54%
Maximum Annual PE Ratio = -3.21
Minimum Annual Increase = -99.92%
Minimum Annual PE Ratio = -4133.28
Year | PE Ratio | Change |
---|---|---|
2023 | -5.83 | 15.34% |
2022 | -5.05 | 57.54% |
2021 | -3.21 | -99.92% |
The current PE Ratio of Nuvectis Pharma, Inc. (NVCT) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-4.70
5-year avg
-1036.84
10-year avg
-1036.84
Nuvectis Pharma, Inc.’s PE Ratio is less than Replimune Group, Inc. (-3.91), less than Lyra Therapeutics, Inc. (-0.17), less than Kronos Bio, Inc. (-0.48), less than Gossamer Bio, Inc. (-2.78), less than Olema Pharmaceuticals, Inc. (-6.37), less than Larimar Therapeutics, Inc. (-8.79), greater than Centessa Pharmaceuticals plc (-11.46), less than Orchestra BioMed Holdings, Inc. (-3.98), less than Monte Rosa Therapeutics, Inc. (-5.06), greater than NewAmsterdam Pharma Company N.V. (-12.84), less than Inventiva S.A. (-1.14), less than Cullinan Oncology, Inc. (-6.51), less than Compass Therapeutics, Inc. (-5.41), less than Ikena Oncology, Inc. (-1.43), less than Aerovate Therapeutics, Inc. (-0.89), less than Eliem Therapeutics, Inc. (-2.42), less than Decibel Therapeutics, Inc. (-1.94), less than Anebulo Pharmaceuticals, Inc. (-5.13), less than Werewolf Therapeutics, Inc. (-1.62), greater than Edgewise Therapeutics, Inc. (-27458.52), less than Celcuity Inc. (-7.38), less than C4 Therapeutics, Inc. (-4.00),
Company | PE Ratio | Market cap |
---|---|---|
-3.91 | $849.92M | |
-0.17 | $17.52M | |
-0.48 | $49.74M | |
-2.78 | $198.83M | |
-6.37 | $710.10M | |
-8.79 | $569.15M | |
-11.46 | $1.87B | |
-3.98 | $233.76M | |
-5.06 | $568.31M | |
-12.84 | $2.17B | |
-1.14 | $240.72M | |
-6.51 | $928.79M | |
-5.41 | $247.66M | |
-1.43 | $84.93M | |
-0.89 | $78.52M | |
-2.42 | $342.68M | |
-1.94 | $123.37M | |
-5.13 | $42.27M | |
-1.62 | $100.52M | |
-27458.52 | $3.41B | |
-7.38 | $586.93M | |
-4.00 | $427.77M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Nuvectis Pharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Nuvectis Pharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Nuvectis Pharma, Inc.'s PE Ratio?
How is the PE Ratio calculated for Nuvectis Pharma, Inc. (NVCT)?
What is the highest PE Ratio for Nuvectis Pharma, Inc. (NVCT)?
What is the 3-year average PE Ratio for Nuvectis Pharma, Inc. (NVCT)?
What is the 5-year average PE Ratio for Nuvectis Pharma, Inc. (NVCT)?
How does the current PE Ratio for Nuvectis Pharma, Inc. (NVCT) compare to its historical average?